[{"id":"68b4f52e-1dcf-41a8-96f4-f19ebb8b9a74","acronym":"","url":"https://clinicaltrials.gov/study/NCT02405338","created_at":"2021-01-18T11:29:06.551Z","updated_at":"2024-07-02T16:36:43.521Z","phase":"Phase 1/2","brief_title":"DC Vaccination for Post-remission Therapy in AML","source_id_and_acronym":"NCT02405338","lead_sponsor":"Medigene AG","biomarkers":" WT1 • PRAME","pipe":"","alterations":" ","tags":["WT1 • PRAME"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CVT-DC-01"],"overall_status":"Completed","enrollment":" Enrollment 20","initiation":"Initiation: 03/01/2015","start_date":" 03/01/2015","primary_txt":" Primary completion: 11/01/2019","primary_completion_date":" 11/01/2019","study_txt":" Completion: 11/01/2019","study_completion_date":" 11/01/2019","last_update_posted":"2020-07-07"}]